Antimicrobial-resistant Nocardia isolates, United States, 1995-2004

Clinical Infectious Diseases

Volumn 51, Issue 12, 2010, Pages 1445-1448

  Uhde, Kristin Broome ^a,b   Pathak, Sonal ^a   McCullum Jr , Isaac ^a   Jannat Khah, Deanna P ^a,c   Shadomy, Sean V ^a   Dykewicz, Clare A ^a   Clark, Thomas A ^a   Smith, Theresa L ^a   Brown, June M ^a  

^a NORTHROP GRUMMAN CORPORATION   (United States)

^b SANOFI PASTEUR   (France)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEFTRIAXONE; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; IMIPENEM; LINEZOLID; MINOCYCLINE; SULFAMETHOXAZOLE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; NOCARDIA; NOCARDIA BRASILIENSIS; NOCARDIA FARCINICA; NOCARDIA NOVA; NONHUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNITED STATES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; NOCARDIA; NOCARDIA INFECTIONS; RETROSPECTIVE STUDIES; UNITED STATES; YOUNG ADULT;

EID: 78649816829     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/657399     Document Type: Article

References (26)

1. Beaman BL, Burside J, Edwards B, et al. Nocardial infections in the United States. J Infect Dis 1976; 134:286-289.
2. Brown-Elliott BA, Brown JM, Conville, PS, et al. Clinical and laboratory features of the Nocardia spp. based on current molecular taxonomy. Clin Micro Rev 2006; 19:259-282.
3. Lederman ER, Crum NF. A case series and focused review of nocardiosis: clinical and microbiologic aspects. Medicine (Baltimore) 2004; 83(5):300-313.
4. Matulionyte R, Rohner P, Uçkay I, Lew D, Garbino J. Secular trends of Nocardia infection over 15 years in a tertiary care hospital. J Clin Path 2004; 57(8):807-812.
5. Saubolle MA, Sussland D. Nocardiosis: review of clinical and laboratory experience. J Clin Microbiol 2003; 41:4497-4501. (Pubitemid 37259748)
6. Torres HA, Reddy BT, Raad II, et al. Nocardiosis in cancer patients. Medicine 2002; 81:388-397.
7. Peleg AY, Husain S, Qureshi ZA, et al. Risk factors, clinical characteristics, and outcome of Nocardia infection in organ transplant recipients: a matched case-control study. Clin Infect Dis 2007; 44:1307-1314.
8. Minero MV, Marin M, Cercenado E, et al. Nocardiosis at the turn of the century. Medicine 2009; 88:250-261.
9. Long PF. A retrospective study of Nocardia infections associated with the acquired immune deficiency syndrome (AIDS). Infection 1994; 22: 362-364.
10. Smego RA, Moeller MB, Gallis HA. Trimethoprim-sulfamethoxazole therapy for Nocardia infections. Arch Intern Med 1983; 143:711-718.
11. Boiron P, Provost F, Chevrier G, Dupont B. Review of nocardial infections in France 1987-1990. Eur J Clin Microbiol Infect Dis 1992; 11:709-714.
12. Kahn Z, Al-Sayer H, Das Chugh T, et al. Antimicrobial susceptibility profile of soil isolates of Nocardia asteroides from Kuwait. Clin Microbiol Infect 2000; 6:94-98.
13. Mootsikapun P, Intarapoka B, Liawnoraset W. Nocardiosis in Srinagarind Hospital, Thailand: review of 70 cases from 1996-2001. Int J Infect Dis 2005; 9(3):154-158.
14. Raymond AS, Moeller MB, Gallis HA. Trimethoprim-sulfamethoxazole therapy for Nocardia infections. Arch Intern Med 1983; 143:711-718.
15. Glupczynski Y, Berhin C, Janssens M, Wauters G. Determination of antimicrobial susceptibility patterns of Nocardia spp. from clinical specimens by Etest. Clin Microbiol Infect 2006; 12:905-912.
16. Huovinen P. Resistance to trimethoprim-sulfamethoxazole. Clin Infect Dis 2001; 32:1608-1614.
17. Clinical and Laboratory Standards Institute/National Committee for Clinical Laboratory Standards (NCCLS). Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes: approved standard. Wayne, PA: NCCLS; 2003:M24-A.
18. National Committee for Clinical Laboratory Standards (NCCLS).Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard. Wayne, PA: NCCLS; 1997:M7-A4.
19. Wallace RJ Jr, Steele LC, Sumter G, et al. Antimicrobial susceptibility patterns of Nocardia asteroides. Antimicrob Agents Chemother 1988; 32:1776-1779.
20. Conville PS, Brown JM, Steigerwalt AG, et al. Nocardia wallacei sp. nov. and Nocardia blacklockiae sp. nov., human pathogens and members of the "Nocardia transvalensis complex." J Clin Microbiol 2008; 46:1178-1184.
21. Desmond EP, Flores M. Mouse pathogenicity studies of Nocardia asteroides complex species and clinical correlation with human isolates. FEMS Microbiol Lett 1993; 110(3):281-284.
22. McNeil MM, Brown JM. Nocardia species (nocardiosis). In: Yu VL, Merigan TC, Barriere SL, eds. Antimicrobial therapy and vaccines. Baltimore: Williams and Wilkins; 1999:310-323.
23. Murph MM, McNeil MM, Brown JM. The changing epidemiology of Nocardia asteroides complex infections, 1993-2000: emergence of Nocardia nova as the predominant pathogen. Paper presented at: Symposium of Latin American Scientists in Biomedical Sciences (SILCIBIO)/Nocardia 2000; University of California at Davis; September 11-15, 2000.
24. Cloud JL, Conville PS, Croft A, et al. Evaluation of partial 16S ribosomal DNA sequencing for identification for Nocardia species by using the MicroSeq 500 system with an expanded database. J Clin Microbiol 2004; 42:578-584.
25. Patel JB, Leonard DGB, Pan X, et al. Sequence-based identification of Mycobacterium species using the MicroSeq 500 16S rDNA bacterial identification system. J Clin Microbiol 2000; 38:246-251.
26. Roth A, Andrees S, Kroppenstedt RM, Harmsen D, Mauch H. Phylogeny of the genus Nocardia based on reassessed 16S rRNA gene sequences reveals underspeciation and division of strains classified as Nocardia asteroides into three established species and two unnamed taxons. J Clin Microbiol 2003; 41:851-856.